Clinical trial
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
NCT00211692 · Minneapolis Veterans Affairs Medical Center, U.S. Fed · Completed
Key facts
| NCT number | NCT00211692 |
|---|---|
| Title | Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial |
| Official title | Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1 |
| Lead sponsor | Minneapolis Veterans Affairs Medical Center, U.S. Fed |
| Collaborators | Center for Veterans Research and Education InterMune Industry Kadmon Corporation, LLC US Department of Veterans Affairs U.S. Fed San Diego Veterans Healthcare System |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin |
| Enrollment | 64 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Sep 1, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 21, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: